In a 14‑year‑old girl with secondary amenorrhea, what diagnostic tests should be performed and what treatment is indicated?

Evaluation and Management of Secondary Amenorrhea in a 14-Year-Old Girl

In a 14-year-old girl with secondary amenorrhea, begin with pregnancy exclusion and a focused endocrine panel (β-hCG, FSH, LH, estradiol, prolactin, TSH, free T4, testosterone, DHEA-S), followed by pelvic ultrasound if anatomic causes are suspected; treatment depends on the underlying diagnosis but most commonly addresses functional hypothalamic amenorrhea through nutritional rehabilitation and stress reduction, or polycystic ovary syndrome through combined hormonal contraceptives. 1, 2

Initial Diagnostic Evaluation

Mandatory First-Line Laboratory Tests

All adolescents with secondary amenorrhea require the following screening panel:

• β-hCG (serum) to definitively exclude pregnancy, as urine tests can be falsely negative in rare cases such as ectopic pregnancy or gestational trophoblastic disease 1, 3
• Complete blood count, electrolytes, glucose, bicarbonate, BUN, creatinine, liver panel to screen for systemic illness, malnutrition, or eating disorders 1
• TSH and free T4 to exclude thyroid dysfunction, which commonly disrupts menstrual cycles 1, 2
• Prolactin (morning, fasting) to detect hyperprolactinemia; levels >20–25 µg/L indicate prolactin-mediated anovulation 1, 2
• FSH, LH, and estradiol measured on cycle days 3–6 (or any time in amenorrhea) to differentiate hypothalamic/pituitary causes from ovarian insufficiency 1, 2
• Testosterone and DHEA-S to screen for hyperandrogenism, particularly if hirsutism, acne, or virilization is present 1, 4
• Anti-Müllerian hormone (AMH) to assess ovarian reserve and support PCOS diagnosis in appropriate clinical contexts 1, 2

Critical History Elements

Obtain detailed information on:

• Diet, eating disorders, weight fluctuations, and body image concerns—functional hypothalamic amenorrhea is strongly associated with restrictive eating and low energy availability 1
• Exercise intensity and duration—training >12 hours/week or participation in low-weight sports (gymnastics, distance running, figure skating) increases risk 1
• Psychological stressors, perfectionism, mood disorders, anxiety, and sleep patterns—stress sensitivity activates the HPA axis and suppresses GnRH drive 1
• Menstrual pattern before amenorrhea—cycles persistently >45 days warrant evaluation even before 3 months of complete amenorrhea 1
• Fracture history—repeated stress fractures occur in up to 30% of ballet dancers and signal low bone mass from energy deficiency 1
• Galactorrhea, headaches, visual changes—suggest hyperprolactinemia or pituitary adenoma 1, 5
• Hirsutism, acne, acanthosis nigricans—indicate hyperandrogenism and possible PCOS 4, 5

Physical Examination Priorities

• Height, weight, BMI, and growth trajectory—assess for malnutrition or excessive weight loss 1, 5
• Vital signs—bradycardia and cool extremities suggest functional hypothalamic amenorrhea 3
• Tanner staging—confirm appropriate pubertal development 1, 5
• External gynecologic examination (and bimanual if sexually active)—exclude anatomic abnormalities such as imperforate hymen or vaginal septum 1
• Signs of hyperandrogenism—hirsutism (Ferriman-Gallwey score ≥4–6), acne, androgenic alopecia 4
• Acanthosis nigricans—marker of insulin resistance in PCOS 4

Diagnostic Algorithm Based on Laboratory Results

Pattern 1: Low-Normal FSH/LH (<10 IU/L) with Low Estradiol (<50 pg/mL)

This pattern indicates functional hypothalamic amenorrhea or central hypogonadism. 1, 2

• Functional hypothalamic amenorrhea is a diagnosis of exclusion—rule out anatomic, organic, and other endocrine pathology first 1
• Screen for eating disorders, excessive exercise, and psychological stressors using validated tools 1
• Obtain bone density assessment (DEXA scan) because prolonged hypoestrogenism causes low bone mass, stress fractures, and impaired peak bone accrual in adolescents 1
• Consider pelvic ultrasound to exclude Müllerian anomalies or intrauterine adhesions (Asherman syndrome) if there is history of postpartum D&C or pelvic infection 1

Pattern 2: Elevated FSH (>25–35 IU/L) with Low Estradiol (<50 pg/mL)

This pattern indicates primary ovarian insufficiency. 2, 5

• Obtain karyotype to exclude Turner syndrome or mosaic variants 5, 6
• Measure AMH—levels <0.5–1 ng/mL confirm diminished ovarian reserve 2
• Counsel that unpredictable ovarian function may persist; spontaneous pregnancy is possible but rare 5, 6

Pattern 3: LH/FSH Ratio >2 with Normal or Elevated Testosterone

This pattern suggests polycystic ovary syndrome. 4, 2

• Confirm clinical or biochemical hyperandrogenism (hirsutism, acne, elevated testosterone or free androgen index) 4
• Document oligomenorrhea (cycles >35 days or <8 cycles/year) persisting >2 years post-menarche 4
• Perform pelvic ultrasound to assess for polycystic ovarian morphology (≥12 follicles 2–9 mm per ovary or ovarian volume >10 mL); note that this finding alone is insufficient for diagnosis in adolescents 4
• Exclude non-classic congenital adrenal hyperplasia by measuring early-morning 17-hydroxyprogesterone; if >200 ng/dL, perform ACTH stimulation test 4
• Screen for metabolic syndrome: fasting glucose, 2-hour oral glucose tolerance test, lipid panel, blood pressure 4

Pattern 4: Elevated Prolactin (>20–25 µg/L)

This pattern indicates hyperprolactinemia. 2, 5

• Obtain brain MRI to exclude pituitary adenoma 5, 7
• Recheck TSH—primary hypothyroidism can cause secondary hyperprolactinemia 2, 5
• Review medications (antipsychotics, metoclopramide, SSRIs) that elevate prolactin 5

Pattern 5: Testosterone >200 ng/dL or Rapid Virilization

This pattern raises urgent concern for androgen-secreting tumor. 4

• Obtain immediate pelvic ultrasound and adrenal CT to detect ovarian or adrenal neoplasm 4
• Refer urgently to endocrinology and surgical oncology 4

Treatment Strategies by Diagnosis

Functional Hypothalamic Amenorrhea

The primary goal is to restore energy balance and reduce stress, not to induce withdrawal bleeding with hormones. 1

• Nutritional rehabilitation: increase caloric intake to achieve positive energy balance; involve a registered dietitian experienced in eating disorders 1
• Reduce excessive exercise: decrease training volume and intensity, particularly in athletes training >12 hours/week 1
• Cognitive-behavioral therapy (CBT) or other psychological support to address stress, perfectionism, and mood disorders 1
• Bone protection: if amenorrhea persists >6 months despite lifestyle modification, consider transdermal estradiol (not oral contraceptives) plus cyclic progestin to optimize bone accrual while minimizing metabolic side effects 1
• Monitor recovery: irregular menses during recovery are normal and do not require immediate re-evaluation; ovulation can occur before regular cycles resume 1

Critical pitfall: Oral contraceptives mask the underlying problem and do not restore bone formation; they should not be first-line treatment for bone health in adolescents with functional hypothalamic amenorrhea. 1

Polycystic Ovary Syndrome

Combined hormonal contraceptives are first-line for menstrual regulation and androgen suppression. 4

• Combined oral contraceptives (estrogen-progestin) regulate cycles, reduce hirsutism and acne, and prevent endometrial hyperplasia 4
• Metformin (1,500–2,000 mg daily) is second-line, particularly effective in overweight adolescents with insulin resistance and acanthosis nigricans 4
• Cyclic progestins (medroxyprogesterone 10 mg for 10–14 days every 1–3 months) are an alternative when contraceptives are contraindicated; they prevent endometrial hyperplasia but do not suppress androgens 4
• Anti-androgens (spironolactone 50–200 mg daily) for persistent hirsutism unresponsive to contraceptives; note this is off-label and contraindicated in pregnancy 4
• Lifestyle modification: 5–10% weight loss in overweight patients improves metabolic parameters and may restore ovulation; prescribe 500–700 kcal/day deficit plus ≥150 min/week moderate-intensity exercise 4
• Long-term metabolic screening: annual fasting glucose, lipid panel, and blood pressure monitoring due to increased risk of type 2 diabetes and cardiovascular disease 4
• Endometrial protection: ensure withdrawal bleeding at least every 3 months to reduce endometrial cancer risk 4

Primary Ovarian Insufficiency

Hormone replacement therapy is essential to support bone health, cardiovascular health, and quality of life. 5, 6

• Transdermal estradiol (titrated to physiologic levels) plus cyclic progestin until age 50–51 years 5, 6
• Contraception counseling: unpredictable ovarian function persists in some patients; spontaneous pregnancy is possible 5, 6
• Bone density monitoring with DEXA scan 5

Hyperprolactinemia

Dopamine agonists are first-line for prolactinomas. 5, 7

• Cabergoline (starting 0.25–0.5 mg twice weekly) or bromocriptine (starting 1.25 mg daily) normalize prolactin and restore ovulation 5, 7
• Treat underlying hypothyroidism if TSH is elevated 5

Bone Health Considerations

Adolescence is the critical window for peak bone mass accrual; prolonged amenorrhea causes irreversible bone loss. 1

• Obtain DEXA scan in any adolescent with ≥6 months of amenorrhea or earlier if severe nutritional deficiency, eating disorder, or fracture history is present 1
• Calcium 1,200–1,500 mg/day and vitamin D 600–1,000 IU/day are foundational 1
• Weight-bearing exercise promotes bone formation, but excessive exercise in energy-deficient states worsens bone loss 1
• Oral contraceptives do not restore bone formation in functional hypothalamic amenorrhea; transdermal estradiol is preferred 1

Follow-Up and Monitoring

• Repeat laboratory testing at 3 months to assess response to treatment 4
• Annual metabolic screening (glucose, lipids, blood pressure) in PCOS patients 4
• Bone density reassessment every 1–2 years in functional hypothalamic amenorrhea or primary ovarian insufficiency 1
• Psychological support throughout treatment, as amenorrhea is associated with anxiety, depression, and disordered eating 1, 5

Critical Pitfalls to Avoid

• Do not diagnose functional hypothalamic amenorrhea without excluding pregnancy, thyroid disease, hyperprolactinemia, PCOS, and primary ovarian insufficiency. 1
• Do not assume polycystic ovarian morphology on ultrasound confirms PCOS in adolescents—this finding can be a normal developmental variant. 4
• Do not prescribe oral contraceptives as first-line bone protection in functional hypothalamic amenorrhea—they mask the problem and do not restore bone formation. 1
• Do not dismiss oligomenorrhea as "normal adolescent irregularity" if it persists >2 years post-menarche—this warrants full evaluation. 1, 4
• Do not overlook eating disorders, excessive exercise, or psychological stressors—these are the most common causes of secondary amenorrhea in adolescents. 1, 5